Related Experiment Video
Updated: Jul 2, 2026
07:36
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
Celecoxib inhibits 5-lipoxygenase
Thorsten J Maier1, Lars Tausch, Michael Hoernig
1Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe-University, Theodor Stern Kai 7, 60590 Frankfurt/Main, Germany. maier@pharmchem.uni-frankfurt.de
Biochemical Pharmacology
|August 12, 2008
Summary
Celecoxib, a COX-2 inhibitor, directly inhibits 5-lipoxygenase (5-LO), an enzyme crucial for leukotriene biosynthesis. This discovery offers a molecular explanation for celecoxib's non-COX-2 related therapeutic effects.
Area of Science:
- Pharmacology
- Biochemistry
- Drug Discovery
Background:
- Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor used for inflammatory and painful conditions.
- Potential COX-2-independent effects of celecoxib, like cancer prevention, are known but lack defined molecular targets.
- Identifying novel targets for existing drugs can reveal new therapeutic applications.
Purpose of the Study:
- To investigate whether celecoxib inhibits 5-lipoxygenase (5-LO), a key enzyme in leukotriene biosynthesis.
- To determine if celecoxib's inhibition of 5-LO is direct and occurs both in vitro and in vivo.
- To explore the potential molecular basis for celecoxib's COX-2-independent pharmacological activities.
Main Methods:
- Celecoxib's effect on 5-LO product formation was assessed in activated human polymorphonuclear leukocytes and whole blood.
- Enzyme kinetics were studied using cell homogenates and purified 5-LO to confirm direct inhibition.
- Inhibition of related lipoxygenases (12-LO, 15-LO) and effects of other NSAIDs on 5-LO were evaluated.
- In vivo studies in rats measured the dose-dependent reduction of blood leukotriene B4 (LTB4) levels after celecoxib administration.
Main Results:
- Celecoxib significantly suppressed 5-LO product formation in human leukocytes and whole blood.
- Direct inhibition of purified 5-LO and 5-LO in cell homogenates by celecoxib was confirmed.
- Celecoxib did not affect related lipoxygenases (12-LO, 15-LO), and other COX-2 inhibitors or NSAIDs did not inhibit 5-LO.
- In rats, celecoxib dose-dependently reduced blood LTB4 levels, indicating in vivo efficacy.
Conclusions:
- Celecoxib is a direct inhibitor of 5-lipoxygenase (5-LO) in both in vitro and in vivo settings.
- This 5-LO inhibitory activity provides a potential molecular mechanism for celecoxib's observed COX-2-independent effects.
- The findings suggest that celecoxib may have broader therapeutic applications beyond its anti-inflammatory actions.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:25Lipid Catabolism
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...